Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 9262909, 6 pages
Clinical Study

Leukocyte-Reduced Platelet-Rich Plasma Treatment of Basal Thumb Arthritis: A Pilot Study

1Department of Trauma Surgery, University Medical Center Regensburg, 93053 Regensburg, Germany
2Institute of Radiology, University Medical Center Regensburg, 93053 Regensburg, Germany
3Department of Orthopedic Surgery, University Hospital Basel, 4056 Basel, Switzerland

Received 23 February 2016; Revised 29 May 2016; Accepted 5 June 2016

Academic Editor: Giuseppe Filardo

Copyright © 2016 Markus Loibl et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


A positive effect of intra-articular platelet-rich plasma (PRP) injection has been discussed for osteoarthritic joint conditions in the last years. The purpose of this study was to evaluate PRP injection into the trapeziometacarpal (TMC) joint. We report about ten patients with TMC joint osteoarthritis (OA) that were treated with 2 intra-articular PRP injections 4 weeks apart. PRP was produced using the Double Syringe System (Arthrex Inc., Naples, Florida, USA). A total volume of  mL PRP was injected at the first injection and  mL at the second injection, depending on the volume capacity of the joint. Patients were evaluated using VAS, strength measures, and the Mayo Wrist score and DASH score after 3 and 6 months. VAS significantly decreased from to at six-month follow-up (). The DASH score was unaffected; however, the Mayo Wrist score significantly improved from to at six-month follow-up (). Grip was unaffected, whereas pinch declined from to at six-month follow-up (). We did not observe adverse events after the injection of PRP, except one occurrence of a palmar wrist ganglion, which resolved without treatment. PRP injection for symptomatic TMC OA is a reasonable therapeutic option in early stages TMC OA and can be performed with little to no morbidity.